A Randomized Double-Blind Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis
Recruiting
18 years - 99 years
All
Phase
3
10 participants needed
1 Location
Brief description of study
Please reference protocol section 2.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Giant Cell Arteritis
-
Age: 18 years - 99 years
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 833643